The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02927340
Recruitment Status : Unknown
Verified January 2021 by Ibiayi Dagogo-Jack, M.D., Massachusetts General Hospital.
Recruitment status was:  Recruiting
First Posted : October 7, 2016
Last Update Posted : March 9, 2021
Sponsor:
Information provided by (Responsible Party):
Ibiayi Dagogo-Jack, M.D., Massachusetts General Hospital

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Unknown
Estimated Primary Completion Date : January 2022
Estimated Study Completion Date : May 2023
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 April 22, 2024
 May 15, 2024
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):